CellTech Leadership

Our Team

James Tsai, Ph.D.,

Founder & COO

Johnny Yu

Founder & Chairman

Chia Ning Shen

Founder & Partner

Ching Lung Hu

Senior Manager

George Su

Program Manager

Patryk Chojecki

Research Associate

Tina Chang

Research Associate

Advisors

Chi Feng Chang

Spike Lo

Mentors

Founder & COO

James Tsai, Ph.D.,

James Tsai, Ph.D., boasts a remarkable track record of success. He has successfully founded and led Deesse Vivante Biomed and Unicocell Biomed to a successful public listing and OTC listing. Furthermore, he has achieved significant accomplishments in the field of clinical product development, spearheading human clinical phase I/IIa trials for allogeneic adipose mesenchymal stem cell therapy for degenerative joint diseases, with TFDA IND approvals at Chang Gung and Tri-Service General Hospitals.

In the realm of GXP, he established Taiwan’s first cell therapy PICS/GMP pilot factory and the country’s first early-stage cell therapy GTP facility, earning recognition from Japan’s PMDA for overseas CPC (cell processing center). Additionally, he obtained TAF ISO/TES 17025 certification in cell therapy and collaborated with multiple hospitals on special permit applications.

His IMPAC award in large-scale production is a testament to his achievements. He developed a semi-automated production line for adherent MSCs, obtained FDA DMF (Drug Master File) certification, and invented the first Class II medical device for automated filling and sealing of cell storage containers.

Founder & Chairman

Johnny Yu

Johnny’s career boasts a standout tenure as the former Vice President at Yuanta Asia Investment, where he excelled in deal sourcing, due diligence, and post-investment management. His accomplishments include significant contributions to M&A, successful private equity fund setup, and fundraising endeavors that have solidified his reputation as an investment maestro.

Moreover, Johnny’s exceptional leadership skills have played a pivotal role in propelling the achievements of distinguished enterprises such as BRIM Biotechnology and Advagene Biopharma. In his capacity as a board director at both BRIM and Advagene, Johnny has consistently demonstrated a hands-on approach, guiding startups from their very inception and skillfully molding their paths towards establishing a prominent presence in their respective industries.

Johnny’s deep market insights and exceptional ability to navigate investment landscapes make him a sought-after expert. His knack for identifying growth opportunities in today’s dynamic market positions him as a key asset for startups aiming to thrive.

Founder & Partner

Chia Ning Shen

Dr. Shen is a dedicated researcher in the fields of stem cells and regenerative medicine. His work focuses on the reprogramming of somatic cells, investigating key mechanisms of cell differentiation and transformation. He has published 90 journal articles, cited nearly 3300 times. His research areas include:

  • Using cell reprogramming techniques to develop diabetes cell therapy strategies.
  • Applying patient-derived induced pluripotent stem cells to study metabolic diseases and develop novel glucose-regulating drugs.
  • Employing 3D tissue imaging and metabolic reprogramming analysis to explore pancreatic tissue transformation mechanisms.
  • Developing gene and cell therapy strategies for pancreatic cancer treatment.

 

Outside of research, Dr. Shen has pursued legal and technology management studies at Taiwan University and National Chengchi University. He has also been involved in various academic roles and served as an executive director. He played a key role in establishing the Taiwan Stem Cell Society and served as its first secretary-general. Additionally, he held the position of president from 2017 to 2021 and is currently an executive director of the Taiwan Cell Therapy Association and the Regenerative Medicine Society, actively involved in promoting legislation and policies related to cell therapy and planning physician training courses. Since January 2019, he has been leading the Biomedical Translation Core Facility, providing technical platforms for the biotechnology research community. From September 2019, he has served as the acting CEO of the Academia Sinica Biomedical Translation Research Center’s Innovation and Incubation Center, supporting the growth of Taiwan’s biotech startups in the national biotech research park.

Senior Manager

Ching Lung Hu

Mr. Hu previously served in the Industrial Development Bureau of the Ministry of Economic Affairs, where he was part of the Biotechnology and Pharmaceutical Industries Promotion Office. He has a deep understanding of the ecosystem and policy resources involving government, academia, research, and healthcare. He has been actively involved in expanding Taiwan’s biotechnology industry and international collaborations.

His contributions include promoting Taiwan’s participation in international conferences and collaborations, such as facilitating Taiwan’s involvement in the APAC conferences organized by the Japan Pharmaceutical Manufacturers Association (JPMA) and the Forum for Innovative Regenerative Medicine (FIRM). He has also fostered partnerships with prominent Japanese biotech companies in the development of innovative drugs. Additionally, he has facilitated interactions and cooperation between Taiwan and the BioIndustry Association of Japan (JBA) in the field of biotechnology.

Furthermore, Mr. Hu has played a role in connecting Taiwan’s academia and industry with pharmaceutical companies from various countries, enabling participation in events like the BIO International Convention and exploring opportunities for collaboration in the field of smart medical devices and biotech in the Southeast Asian region.

Program Manager

George Su

George is an accomplished professional with a degree from San Jose State University, where he has honed his skills and expertise. He currently serves as a Project Manager at both Mosaic Venture Lab and CellTech Innovation Venture Studio, where he has consistently demonstrated exceptional abilities in managing projects and initiatives.

George stands out for his excellent communication skills, which allow him to effectively liaise with team members, stakeholders, and partners. His ability to convey ideas clearly and facilitate collaboration has been instrumental in the successful execution of various projects.

In addition to his communication prowess, George excels in problem-solving and critical thinking. He has a knack for identifying challenges, analyzing complex situations, and devising innovative solutions. His strategic mindset is evident in his approach to project planning and execution.

George also brings a solid foundation in strategic planning to the table. He possesses a keen understanding of how to align project goals with broader organizational objectives, ensuring that every initiative contributes to the overall success of the company.

Research Associate

Patryk Chojecki

Patryk Chojecki is an up-and-coming professional with a master’s degree in International Affairs from National Chengchi University. In the early stages of his career, Patryk gained valuable experience as a Research Assistant at Academia Sinica, making significant contributions to projects related to the US government. Additionally, he served as a Contributing Researcher at the Taiwan Architecture & Building Center (TABC), where he forged partnerships with European companies and authored articles on governance, the economy, and ESG investing. Patryk’s passion for economics, politics, and his growing interest in future startup ventures reflect his potential to make meaningful contributions to the global biotech landscape.

Research Associate

Tina Chang

Tina holds a master’s degree in chemistry with a focus on chemical biology from National Taiwan University. She bridges the worlds of biology and chemistry, transitioning from academia to serving clients in the biotech and pharmaceutical industries.

During her academic tenure, she published papers in the field of biological analysis and collaborated with hospitals and universities on research projects. In her role at a startup pharmaceutical development company, Tina engaged in patent process development, optimizing API physical properties through specialized processes, and gained insight into the unique resource requirements and allocation challenges faced by startups.

As an associate manager, she provided bio-pharmaceutical process analysis and recommendations to biotech, academic research, and government organizations, contributing to the foundation of clinical success. Tina furthered her education by completing a management master’s program, combining her scientific background with skills in marketing, strategic planning, and business modeling to offer clients comprehensive solutions.

Currently, her mission is to leverage her experiences to assist startup industry clients in optimizing resource allocation.

Advisor

Li Ju Wang

Dr. Wang currently serves as the Director of the Drug Commercialization Center at the Development Center for Biotechnology. In this role since April 2017, she oversees the center’s overall operations and provides services such as technology market analysis, patent strategy, analysis, and technology commercialization support. Her focus is to assist academia and industry in overcoming challenges in the drug commercialization process.

With over 11 years of experience as the principal investigator for national biotechnology projects, she has a wealth of accomplishments and expertise in advancing the commercialization of biopharmaceuticals and biotechnology medicines. Dr. Wang possesses nearly 20 years of experience in patent analysis, consulting/strategy, patent mapping, and patent infringement identification in industrial practice. She holds national licenses as a patent attorney, food technologist, and nutritionist. Due to her extensive experience in patent and commercialization guidance, she has been appointed as a review committee member for organizations such as the National Biotechnology Research Park and the Taiwan Bio Industry Organization.

Under her leadership, her team has facilitated over 80 technology commercialization achievements in the past decade, including technology licensing agreements, industry-academia collaboration projects, and the establishment of startup companies, totaling investments exceeding 2.5 billion New Taiwan Dollars.

© 2023 Celltech Innovation Venture Studio Co., Ltd.